Idiopathic pulmonary fibrosis (IPF) is characterized by accumulation of extracellular matrix (ECM) proteins and fibroblast proliferation. ECM cross-linking enzymes have been implicated in fibrotic diseases, and we hypothesized that the ECM in IPF is abnormally cross-linked, which enhances fibroblast growth and resistance to normal ECM turnover. We used a combination of in vitro ECM preparations and in vivo assays to examine the expression of cross-linking enzymes and the effect of their inhibitors on fibroblast growth and ECM turnover. Lysyl oxidase-like 1 (LOXL1), LOXL2, LOXL3, and LOXL4 were expressed equally in control and IPF-derived fibroblasts. Transglutaminase 2 was more strongly expressed in IPF fibroblasts. LOXL2-, transglutaminase 2-, and transglutaminase-generated cross-links were strongly expressed in IPF lung tissue. Fibroblasts grown on IPF ECM had higher LOXL3 protein expression and transglutaminase activity than those grown on control ECM. IPFderived ECM also enhanced fibroblast adhesion and proliferation compared with control ECM. Inhibition of lysyl oxidase and transglutaminase activity during ECM formation affected ECM structure as visualized by electron microscopy, and it reduced the enhanced fibroblast adhesion and proliferation of IPF ECM to control levels. Inhibition of transglutaminase, but not of lysyl oxidase, activity enhanced the turnover of ECM in vitro. In bleomycintreated mice, during the postinflammatory fibrotic phase, inhibition of transglutaminases was associated with a reduction in whole-lung collagen. Our findings suggest that the ECM in IPF may enhance pathological cross-linking, which contributes to increased fibroblast growth and resistance to normal ECM turnover to drive lung fibrosis.
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia, with an incidence of 7.44 per 100,000 person-years and a prevalence that is rising year on year (1) . The lung architecture is progressively remodeled by the proliferation of fibroblasts and myofibroblasts as well as the deposition of extracellular matrix (ECM), leading to respiratory failure with a median survival of less than 3 years (2) .
The deposition of fibrosis in IPF is heterogeneous, both in its spatial distribution and its evolution over time. Regions of densely packed fibroblasts/myofibroblasts and ECM proteins, particularly collagen I, termed fibroblast foci, tend to be situated adjacent to less involved regions of the lung (3) . The activated myofibroblast is thought to be the main source of pathological ECM in IPF and to be present in the fibroblast foci and the less densely involved areas of the lung (4) . The mammalian ECM consists of around 300 individual proteins, which include the classical ECM proteins, including collagens, fibronectin, elastin, proteoglycans, and glycoproteins, but also a large number of signaling molecules, post-translational modifying enzymes, and proteases. The ECM is a dynamic and versatile part of the cellular environment, influencing almost all cell functions, including proliferation and migration by binding to growth factors, by acting as a coreceptor for various ligands and signaling via endogenous growth factor domains or matricryptins generated by proteolytic processing (5, 6) . Additionally, changes in the biomechanical properties of the ECM can induce gene expression programs affecting cell differentiation and function (7) . Consistent with the ECM's importance, multiple levels of regulation ensure tight control of ECM production, degradation, and remodeling (8) . However, in fibrotic diseases and cancers, abnormal ECM dynamics and organization are major drivers of abnormal cell behavior and ultimately organ failure (9) .
In addition to ECM proteins, matrixdegrading proteases, including matrix metalloproteinases (MMPs) 1 and 7, a disintegrin-like and metalloprotease with thrombospondin type 1 motif (ADAMTS)-1, and ADAMTS-5 are strongly overexpressed in IPF (10) , suggesting that the accumulation of ECM in IPF may not be due to suppression of MMP activity as previously thought (11) . A potential explanation for the increase in both ECM proteins and proteases is that the ECM in IPF may be abnormally resistant to ECM-degrading proteases. Stabilization of the ECM by cross-linking of collagen/fibronectin by transglutaminase 2 (TG2) (12) and collagen/elastin by lysyl oxidase-like 2 (LOXL2) (13) , respectively, can protect the ECM from proteolysis in other organs (14, 15) .
TG2 is an 80 kD protein with a number of enzymatic and nonenzymatic functions. TG2 cross-links the ECM by calciumdependent transamidation/deamidation of the glutamine or lysine side chains of many proteins, resulting in lysine cross-link formation. LOXL2 is a member of the lysyl oxidase (LOX) gene family, whose members share conserved C-terminal copper-binding and catalytic domains and act as extracellular copper-dependent amine oxidases that deaminate the lysine e-amino group to cross-linkage collagen and elastin monomers (16) . Both TG2 and LOXL2 are overexpressed in IPF, and their inhibition or absence during the induction of fibrosis reduces lung inflammation and fibrosis in bleomycin-treated animals (12, 13) . In the present study, we tested the hypotheses that the ECM in IPF is aberrantly cross-linked, supports fibroblast growth, and confers resistance against ECM turnover by proteolysis, as well as that inhibition of ECM cross-linking can affect these processes.
Methods
Full details of all methods and supporting data are provided in the data supplement.
Cells, Tissues, and Serum Samples IPF-derived fibroblasts were obtained from patients undergoing lung biopsy for the diagnosis of interstitial lung disease. Control fibroblasts were obtained from patients undergoing lung tumor resections from uninvolved areas of the specimen. Cells were cultured in Dulbecco's modified Eagle's medium containing 10% FBS and were characterized by immunostaining for a-smooth muscle actin (a-SMA), S100A4, and fibroblast activation protein (see Figure  E1 in the data supplement). IPF and control lung tissues were obtained from the Nottingham Health Science Biobank. IPF and control sera with linked clinical data were obtained from the Trent Lung Fibrosis Study, which has been described previously (17) . The use of cells, tissues, and sera was approved by the Nottingham Research Ethics Committee, and all patients provided written informed consent.
ECM Preparations and Assays
ECM was obtained from three IPF-derived and three control fibroblast cultures as described elsewhere (18) . ECM protein was analyzed in two fractions, one soluble in RIPA buffer (soluble fraction) and the other isolated by physical scraping and solubilization in an 8 M urea-based buffer (insoluble fraction). ECM structure was visualized by electron microscopy using a JEOL 6060LV scanning electron microscope (JEOL Ltd.). For ECM degradation assays, fibroblasts were incubated with 1 µCi/ml tritiated proline during matrix deposition. Tritiated proline-labeled ECM preparations were digested with recombinant MMPs 1, 2, and 7 (R&D Systems), and tritium was measured in the soluble fraction by scintillation counting and expressed as disintegrations per minute (DPM) as a marker of ECM proteolysis. The effect of ECM stiffness on TG2 activity was analyzed by culturing control fibroblasts on substrates of variable stiffness (SoftSubstrates). In vitro TG2 cross-linking was performed by incubation of recombinant human TG2 protein (500 ng/ml) or controls with 50 mg/ml collagen type I (Advanced Biomatrix) and 50 mg/ml fibronectin (Sigma-Aldrich) overnight at 37 8 C on a rotating shaker.
In vitro Cell Proliferation, Adhesion, and Apoptosis Assays Fibroblasts were cultured on ECM preparations for 48 hours, and cell growth/proliferation was determined by MTT reduction assay, 5-ethynyl-29-deoxyuridine DNA incorporation, and cell counting as described previously (19) . For adhesion assays, fluorescently labeled control fibroblasts were seeded onto ECM preparations, and adherent cells were measured by average well fluorescence after 2 hours. Apoptosis was assessed using the In Situ Cell Death Detection kit, AP (Roche Diagnostics).
Cross-Linking Enzyme Analysis
Gene expression for LOX, LOXL1-LOXL4, and TG2 in IPF-derived and control fibroblasts grown on IPF and control matrix were measured by using b-actin as the reference gene, as described in the data supplement. TG2 and LOXL3 proteins were measured by ELISA (CUSABIO Biotech Co. Ltd. and Cloud-Clone Corp.). Transglutaminase activity was determined using the Transglutaminase Assay Kit (Sigma-Aldrich), and LOX activity was determined using a fluorometric LOX activity assay kit (Abcam). Immunohistochemistry was performed as described previously (20) .
Bleomycin Model of Fibrosis
Six-to 8-week-old C57BL/6 mice received 60 IU of intratracheal bleomycin as described elsewhere (21) . Starting either 14, 24, or 34 days later, intraperitoneal cystamine (100 mg/kg) was administered daily for 10 days. Mice were then killed by terminal anesthesia; blood samples were taken; and the lungs were excised and snap frozen. Total lung collagen was assessed by hydroxyproline assay as described previously (22 We examined the expression of the LOX and transglutaminase family enzymes in control and IPF-derived fibroblasts cultured on tissue culture plastic by real-time qRT-PCR. LOXL1-LOXL4 mRNAs were detected in all cells with expression not significantly different between control and IPF-derived fibroblasts. The LOX transcript was also present in all cells, but at very low levels. The TG2 transcript (TGM2) was expressed in normal fibroblasts and over 70-fold more strongly in IPF-derived fibroblasts (control, 2.90; IPF, 177.5; n = 3; P , 0.05). TG6 and TG7 transcripts were not present in either cell type ( Figure 1 ). Total ECM protein, total collagen, collagen synthesis ( Figure  E2 ), and collagen isoform gene expression did not vary between IPF and control fibroblast ECM ( Figure E3 ).
We then examined cross-linking enzymes N-e g-glutamyl lysine cross-links, a-SMA, and collagen using picrosirius red and the proliferation marker Ki-67 in lung tissue from three control and eight patients with IPF. TG2 and N-e g-glutamyl lysine cross-links are present in control alveolar epithelium and strongly expressed in all areas of IPF tissue. Immunostaining for TG2 and the TG2 cross-link was ubiquitous in all areas of IPF tissue, including those with dense fibrosis, regions less involved by fibrosis, and fibroblast foci. TG2 and its associated cross-link paralleled the deposition of collagen and a-SMA in lung tissue. Proliferating cells identified by Ki-67 positivity were present in all areas of IPF tissue ( Figure 2 ). Within areas of dense fibrosis and fibroblast foci, proliferating cells tended to have fibroblast morphology, whereas in areas of lesser fibrosis, they had a morphology consistent with inflammatory cells. LOXL2 was expressed in control and IPF tissue. LOXL3 was not expressed in normal lung tissue and was present at low levels in IPF tissue, although positive control tissue (small intestine; not shown) stained more strongly ( Figure E4 ).
To determine the systemic expression of these cross-linking enzymes in patients with IPF, we studied levels of circulating LOXL3 and TG2 in 60 patients with IPF, 30 of whom had died within 1 year of recruitment, 30 of whom had survived for more than 1 year, and 30 who were age-and sex-matched control subjects. There were no significant differences for either LOXL3 or TG2 between those with IPF and agematched control subjects. For all 60 with IPF, there was no association between serum LOXL3 or TG2 and FVC. Similarly, there was no difference between serum LOXL3 or TG2 levels between patients who were alive or who had died ( Figure E7 ).
IPF Matrix Induces LOXL3 and TG2 Expression
We hypothesized that ECM derived from IPF fibroblasts may promote its own crosslinking. To test this, we produced ECM from fibroblasts derived from three control subjects and three patients with IPF. All six cell types were seeded onto each matrix type, and cross-linking gene expression was examined by real-time qRT-PCR. LOXL3 was strongly induced in both cell types when grown on IPF-derived ECM, with the matrix type accounting for 75.5% of total variation (P , 0.001) ( Figure 3A ). TG2 Transglutaminase 2 (TG2) mRNA was expressed at a significantly higher level in the IPF-derived fibroblasts. TG6 and TG7 were not detected. ACTA2 was used as a positive control. ***P , 0.001. Data were analyzed with multiple unpaired t tests corrected for multiple comparisons using the HolmSídák method. Data are presented with SD; n = 3. Figure 3 . IPF-derived ECM induces LOXL3 protein and transglutaminase activity. (A) Three control and three IPF-derived fibroblasts were cultured on three control and three IPF-derived ECM preparations, and gene expression for cross-linking enzymes was quantified by real-time PCR. TG2 mRNA tended to be more strongly expressed in IPF fibroblasts regardless of matrix substrate, although this was not significant. LOXL3 was strongly induced on IPF-derived ECM in both cell types. LOX was weakly expressed on control ECM and further suppressed on IPF-derived ECM. (B) TG2 cross-linking activity measured in three control and IPF fibroblasts was higher in IPF-derived than control cells. IPF-derived matrix enhanced TG2 in control but not IPF-derived fibroblasts. *P , 0.05. (C) LOXL3 protein is strongly induced on IPF-derived ECM. ***P , 0.0001 (two-way repeated measures ANOVA). AU = arbitrary units.
mRNA showed a trend toward increased expression in IPF-derived fibroblasts over control cells independent of matrix substrate; however, this was not significant. Other cross-linking enzymes did not vary with cell or ECM type.
Transglutaminase activity and LOXL3 protein were measured in supernatants from these cultures. Transglutaminase activity in supernatants increased in a cell-dependent manner. IPF fibroblasts on control matrix had increased TG2 activity over control cells on control matrix (control, 0.22 AU; IPF, 0.36 AU; n = 3; P , 0.05). In addition, TG2 activity increased twofold when control fibroblasts were seeded onto IPF ECM compared with control matrix (control, 0.22 AU; IPF, 0.42 AU; n = 3; P , 0.01) ( Figure 3B and Figure E5 ). Consistent with the gene expression data, LOXL3 protein expression was upregulated 3.3-fold in control fibroblasts grown on IPF compared with control matrix (control, 280.4 pg/ml; IPF, 922.9 pg/ml; n = 3; P , 0.001) and 4.2-fold in IPF fibroblasts grown on IPF compared with control matrix (control, 248.9 pg/ml; IPF, 1,053 pg/ml; n = 3; P , 0.001) ( Figure 3C ). To determine if the observed changes were due to enhanced ECM stiffness, we examined the transglutaminase activity of fibroblasts grown on substrates with a Young's modulus varying between 0.5 and 64 kPa, and we found that ECM stiffness had no effect on transglutaminase activity ( Figure E8 ).
IPF Matrix Enhances Fibroblast Adhesion and Proliferation
To determine whether IPF-derived ECM contributes to an environment that supports expansion of the fibroblast population, we examined adhesion, proliferation, and resistance to apoptosis of fibroblasts on control and IPF-derived ECM. IPF-derived ECM enhanced control and IPF-derived fibroblast adhesion by 2.4-fold (P , 0.05) and 7.5-fold (P , 0.01), respectively, over control ECM ( Figure 4A ). In the absence of a mitogen, MTT reduction and DNA synthesis did not differ when cultured on IPF-derived and control ECM for 48 hours. Stimulating growth with either 1% FBS or platelet-derived growth factor-BB (5 ng/ml) . IPF-derived ECM enhances fibroblast adhesion, MTT reduction, and DNA synthesis. (A) Adhesion of three control and three IPF-derived fibroblasts was quantified on tissue culture plastic (none) and three control and IPF-derived ECM preparations and repeated three times. Both matrices significantly enhanced adhesion of normal fibroblasts. IPF matrix significantly enhanced adhesion of both fibroblast types over control matrix. IPF-derived ECM increased (B) MTT reduction and (C) DNA synthesis in cells treated with 1% FBS and platelet-derived growth factor-BB (PDGF-bb) for 48 hours (*P , 0.05; **P , 0.01; and ***P , 0.001; multiple t tests with Holm-Šídák correction).
enhanced control fibroblast MTT reduction on IPF-derived ECM by 26-fold (P , 0.0001) and 17-fold (P , 0.01), respectively, and DNA synthesis, as measured by 5-ethynyl-29-deoxyuridine incorporation by 1.2-fold (P , 0.01) and 1.2-fold (P , 0.05), respectively ( Figure 4B ). IPF-derived ECM had no effect on fibroblast apoptosis induced by either staurosporine or Fas ligand as judged by DNA fragmentation, caspase 3, or PARP cleavage ( Figure E6 ).
Enhanced Adhesion and Proliferation on IPF-derived ECM Is Dependent on Matrix Cross-Linking
We then examined if the functional effects of IPF-derived ECM were a consequence of ECM cross-linking. ECM preparations were produced by cells treated with inhibitors of TG2 (cystamine dihydrochloride) and the LOX family (b-aminopropionitrile [b-APN]). Treatment of cells with these inhibitors had no effect on the amount of ECM deposition or cell viability (data not shown). To determine whether cystamine and b-APN affected ECM structure, we examined the ECM deposited by both cell types and the effect of the cross-link inhibitors using scanning electron microscopy. Both cystamine and b-APN disrupted the ordered ECM fibrillary structure ( Figure 5A ). The enhanced fibroblast adhesion on IPF-derived ECM was reduced to a level similar to that of control ECM by both cystamine (vehicle, 334.0 AU; cystamine, 283.2 AU; P , 0.0001; n = 3) and b-APN (vehicle, 334.0 AU; b-APN, 254.2 AU; P , 0.0001; n = 3) ( Figure 5B ). Enhanced fibroblast proliferation was reduced 6.5-fold by cystamine treatment of IPF ECM (vehicle, 0.478 AU; cystamine, 0.073 AU; P , 0.01; n = 3). Cystamine treatment of control ECM resulted in a paradoxical increase in MTT reduction in control cells. b-APN inhibited proliferation on IPF ECM in a manner similar to cystamine by 3.4-fold (vehicle, 0.478 AU; b-APN, 0.139 AU; P , 0.05; n = 3) ( Figure 5C ).
To ensure that these observations were not due to a nonspecific effect of cystamine, we first examined LOX activity in cystamine-treated cells and found no effect of cystamine on LOX cross-linking activity (data not shown). We next performed fibroblast adhesion and proliferation assays on in vitro cross-linked collagen/fibronectin-coated plates that had been incubated with either vehicle control, recombinant TG2 (500 ng/ml), or TG2 and cystamine. Adhesion of MRC-5 fibroblasts to this ECM coating was enhanced 2.1-fold (P , 0.05) by TG2 treatment. Coincubation with cystamine completely abrogated the increased adhesion ( Figure 5D ). Cell number in response to 1% serum over 72 hours was enhanced 1.4-fold (P , 0.05) by TG2 treatment, and the increase was blocked by cystamine ( Figure 5E ). We then examined the colocalization of the TG2-associated cross-link and proliferating cells identified by Ki-67 staining in eight IPF lung samples. Both the cross-link and Ki-67-positive cells were ubiquitous in the IPF lung. In regions of less dense fibrosis, the proliferating cell morphology was similar to that of macrophages. Mature fibrotic regions and fibroblast foci contained more densely packed structural cells and ECM, where the Ki-67-positive cells were likely to be myofibroblasts. Within the densely fibrotic regions, there was no association between the cross-linking and proliferation at the single time point examined ( Figure E9 ).
Transglutaminase Inhibition Enhances Matrix Proteolysis
We next asked if abnormal matrix crosslinking conferred resistance to proteolysis. ECM preparations were generated, incorporating tritiated proline and the release of tritium into supernatants taken as a measure of matrix proteolysis. In all ECM preparations, a low level of spontaneous ECM turnover was observed. Treatment of IPF fibroblasts during ECM deposition with the TG2 inhibitor cystamine increased spontaneous ECM turnover (vehicle, 202 DPM; cystamine, 549 DPM; P , 0.01; n = 3). To determine if the observed spontaneous ECM turnover was due to ECM-resident proteases, we treated the formed ECM preparations with a broad-spectrum protease inhibitor that tended to reduce spontaneous ECM turnover. Addition of active MMP-1 had no further effect on ECM turnover in either control or cystamine-treated IPF ECM preparations ( Figure 6 ). Direct activation of resident MMPs by the addition of 4-aminophenylmercuric acetate (APMA) enhanced the turnover of IPF ECM formed in the presence of cystamine from all IPFderived cells; however, the effect varied between cells and did not achieve significance. Addition of activated MMP-1, -2, or -7 had no additional effect over the APMA vehicle. Cystamine had no effect on control ECM turnover, and the LOX family inhibitor b-APN had no effect on proteolysis of either control or IPF-derived ECM ( Figure E10 ).
In vivo Inhibition of TG2
To determine if inhibition of transglutaminases in vivo would result in increased ECM turnover and a net reduction in fibrosis, we examined the effect of cystamine in the mouse bleomycin model of fibrosis. In preliminary experiments, we confirmed that bleomycin treatment of lung tissue resulted in increased transglutaminase activity. Ex vivo incubation of murine lung tissue with bleomycin resulted in a 2.2-fold increase in transglutaminase activity (P , 0.001; n = 3), which was almost completely abrogated by cystamine (P , 0.05; n = 3) ( Figure 7A ). Following this, we performed a time-course experiment and determined that the level of fibrosis no longer increased 24 days after bleomycin administration ( Figure E11 ). In the mouse model, cystamine administration from 24 to 34 days after bleomycin exposure was associated with a 24% reduction in total lung hydroxyproline (vehicle, 1,593 µg; cystamine, 1,198 µg; P , 0.05; n = 3) but had no effect hydroxyproline in salinetreated animals ( Figure 7B ).
Discussion
We have shown that IPF-derived ECM is strongly cross-linked and supports increased fibroblast adhesion and proliferation. Moreover, disruption of ECM cross-linking in vitro affects ECM structure and reduces enhanced fibroblast adhesion and proliferation, and inhibition of transglutaminases in vivo enhances ECM turnover. Furthermore, expression of TG2 and the LOXL family in IPF are both ECM and cell dependent. Collectively, these findings suggest that IPF ECM is abnormally cross-linked and that this crosslinking is one factor that supports fibrosis by enhanced fibroblast growth and resistance to normal ECM turnover.
The induction of the ECM crosslinking enzymes TG2 and LOXL3 by IPF ECM is consistent with the observations of Parker and colleagues, who demonstrated that fibrotic ECM induces multiple profibrotic gene expression programs (23) . Collectively, these observations are consistent with fibrotic changes creating an environment that sustains further fibrosis and tissue remodeling. A number of potential mechanisms could explain the enhanced fibroblast adhesion and proliferation on fibrotic ECM. The increased activity of TG2 in IPF derived fibroblasts results in an increase in N-e g-glutamyl lysine cross-links between collagen and fibronectin. The alterations in ECM structure as a consequence of increased cross-linking may result in increased access to ECM proadhesive and proliferative signals and reduced adhesion and proliferation caused by inhibition of both TG2 and the LOXL family would be consistent with this. The larger increase in metabolic activity (MTT reduction) compared with the more modest increase in DNA synthesis may suggest that IPF matrix also has effects upon fibroblast metabolism. In addition, transglutaminase activity Figure 6 . Tritiated hydroxyproline release from IPF ECM is due to endogenous proteases. Liberation of radiolabeled collagen fragments from ECM derived from IPF fibroblasts treated with either cystamine or vehicle, normalized to scintillant-only background, shows increased proteolysis after TG2 inhibition during synthesis. Cystamine treatment of IPF ECM enhances spontaneous ECM turnover, which is reduced by a broad-spectrum protease inhibitor (protease i) but is not further increased by active matrix metalloproteinase 1 (MMP-1). *P , 0.05. enhances fibronectin deposition, and changes in ECM proteins may affect adhesion and proliferation (12) . Enhanced cross-linking may also alter ECM stiffness, which is a driver of cell growth and survival as well as gene transcription; however, any such effect seems independent of TG2 activity, which was unaffected by ECM stiffness in our study. It is also possible that the cross-links themselves are capable of outside-in signaling to fibroblasts, enhancing adhesion and proliferation.
Whereas IPF-derived cells have higher transglutaminase activity on control ECM, IPF-derived ECM induces transglutaminase activity in control fibroblasts. Our data therefore suggest that both the cell and ECM origin determine transglutaminase activity. It is possible that the effect of IPF ECM may lead to permanent changes in gene expression. The study by Parker and colleagues suggested that although the ECM was the primary driver of fibrotic gene expression by modulation of the profibrotic microRNA miR-29, the cell type contributed synergistically to fibrotic gene expression (24) . Recent genetic studies suggest that IPF fibroblasts may have both genetic (25) and potentially acquired epigenetic differences (26) , which may account for differences in gene expression.
The TG2-generated N-e g-glutamyl lysine cross-link is resistant to proteolysis by MMP-1 and -2 in vitro, and reduced crosslinking is likely to explain the increase in ECM turnover induced by the TG2 inhibitor (27) . Interestingly, we observed that the TG2 inhibitor cystamine enhanced constitutive or spontaneous ECM turnover that was inhibited by a broad-spectrum protease inhibitor and enhanced by APMA, an activator of MMPs. ECM proteolysis was not further enhanced by endogenous MMP-1, -2, or -7, proteases that are overexpressed in the lungs of those with IPF. Our findings are consistent with the presence of MMPs in the ECM preparation causing constitutive ECM turnover. Proteomic analysis of the ECM confirms the presence of multiple collagenolytic MMPs that could be activated by APMA and also ADAMTS, serine proteases, and cathepsins (28) .
Intratracheal administration of bleomycin in vivo results in a strong inflammatory reaction leading to collagen deposition resolving over 14-21 days, followed by the persistence of excess collagen in the absence of inflammation (29) . TG2 is a multifunctional protein with intra-and extracellular enzymatic and nonenzymatic actions in inflammation, cell death, and survival (30) . In TG2-knockout animals, bleomycin-induced lung fibrosis is reduced during the inflammatory and fibrotic phases of the model (12) . We used a TG2 inhibitor during the established fibrotic phase of the model and observed a small reduction in total lung collagen at a point when the fibrosis had become established. We suspect that in addition to the antiinflammatory effect on the generation of fibrosis observed by Olsen and colleagues, the effect on lung collagen seen in this model was likely to have been produced by the reduction in fibrosis-driven transglutaminase cross-linking, allowing protease-mediated ECM turnover. The combination of interruption of the proposed transforming growth factor-b/TG2 profibrotic feedback loop, reduction of fibroblast growth, and restoration of normal ECM turnover may contribute to reduction of the progression of fibrosis (12) . Taken together, our data suggest that inhibition of TG2 in fibrosis may reduce the burden of fibrosis by multiple mechanisms. Recently, inhibition of the cross-linking enzyme LOXL2 using a monoclonal antibody proved unsuccessful as a therapy for IPF (31) . The multiple cross-linking enzymes present in fibrotic lung tissue are likely to fulfill different functions, and inhibition of TG2 remains a potential target in human lung fibrosis.
In conclusion, we have found that inhibition of TG2-mediated cross-link formation reduces fibroblast adhesion and proliferation and enhances the turnover of ECM produced by IPF fibroblasts. These findings suggest that inhibition of transglutaminase cross-linking may be a potential therapy for IPF. n 
